Brown, Lisle/Cummings’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.87M | Buy |
56,054
+125
| +0.2% | +$8.63K | 1.03% | 23 |
|
|
2025
Q1 | $3.88M | Buy |
55,929
+7,071
| +14% | +$491K | 1.13% | 20 |
|
|
2024
Q4 | $4.2M | Sell |
48,858
-1,337
| -3% | -$115K | 1.25% | 18 |
|
|
2024
Q3 | $5.98M | Buy |
50,195
+7,200
| +17% | +$857K | 1.82% | 10 |
|
|
2024
Q2 | $6.14M | Sell |
42,995
-1,070
| -2% | -$153K | 2% | 9 |
|
|
2024
Q1 | $5.66M | Sell |
44,065
-225
| -0.5% | -$28.9K | 1.92% | 9 |
|
|
2023
Q4 | $4.58M | Buy |
44,290
+7,000
| +19% | +$724K | 1.7% | 10 |
|
|
2023
Q3 | $3.39M | Buy |
37,290
+3,700
| +11% | +$336K | 1.53% | 15 |
|
|
2023
Q2 | $2.72M | Sell |
33,590
-430
| -1% | -$34.8K | 1.22% | 21 |
|
|
2023
Q1 | $2.71M | Sell |
34,020
-7,430
| -18% | -$591K | 1.37% | 17 |
|
|
2022
Q4 | $2.8M | Hold |
41,450
| – | – | 1.51% | 16 |
|
|
2022
Q3 | $2.06M | Sell |
41,450
-250
| -0.6% | -$12.5K | 1.21% | 20 |
|
|
2022
Q2 | $2.32M | Sell |
41,700
-450
| -1% | -$25.1K | 1.29% | 19 |
|
|
2022
Q1 | $2.34M | Buy |
42,150
+4,800
| +13% | +$267K | 1.12% | 21 |
|
|
2021
Q4 | $2.09M | Buy |
+37,350
| New | +$2.09M | 1.05% | 21 |
|